Biological Testing Facility for Contraception Reproductive Health (X01 Clinical Trial Not Allowed)

The Biological Testing Facility for Contraception & Reproductive Health funding opportunity is issued by the National Institutes of Health, within the U.S. Department of Health and Human Services, specifically through the Eunice Kennedy Shriver National Institute of Child Health and Human Development. This program reflects the agency’s longstanding role in advancing biomedical research that improves reproductive health outcomes and expands contraceptive options. The initiative is structured as a service-based grant mechanism rather than a traditional monetary award, designed to provide investigators with access to specialized biological testing infrastructure that may otherwise be inaccessible. The primary purpose of this funding opportunity is to support researchers in advancing contraceptive development and reproductive health innovations by offering access to a state-of-the-art Biological Testing Facility. Rather than distributing direct funding to support independent project budgets, the program enables investigators to request testing services that can validate, refine, and accelerate their research. These services are intended to position projects for future regulatory submissions or progression into clinical development pipelines. The emphasis is on supporting innovative and validated methods that can demonstrate readiness for further development stages. Allowable use under this opportunity is therefore limited to the utilization of facility-based services provided through the program. Applicants are expected to submit proposals that clearly define how access to these testing resources will advance their specific contraceptive or reproductive health research goals. Because this is an X01 mechanism, no clinical trials are permitted under this opportunity. There is no cost-sharing or matching requirement, lowering barriers to entry for a wide range of applicants, including those without current NIH funding, although preference may be given to projects already supported by NIH at the time of submission. Eligibility for this opportunity is broad and inclusive, encompassing a wide spectrum of organizational types. Eligible applicants include nonprofit organizations with or without 501(c)(3) status, small and large for-profit entities, institutions of higher education (both private and public), state and local government entities, tribal governments and organizations, independent school districts, and special district governments. Additionally, foreign organizations are eligible to apply, though foreign components of U.S.-based organizations are not permitted. This inclusive eligibility framework reflects NIH’s intent to foster collaboration and innovation across sectors and geographic boundaries. The application process requires submission through the appropriate NIH channels, typically involving standard federal grant submission systems such as Grants.gov. Applicants must prepare and submit a proposal detailing their research objectives, the specific services requested from the Biological Testing Facility, and the anticipated impact on contraceptive or reproductive health development. While detailed application components are not explicitly listed in the synopsis, standard NIH application requirements are expected to apply, including project descriptions, investigator qualifications, and compliance documentation. The timeline for this opportunity indicates that applications are currently being accepted, with a closing date of May 7, 2029. The program appears to be part of a recurring or long-term NIH initiative, though explicit recurrence language is not provided. Applicants are encouraged to plan submissions well in advance of the deadline to ensure adequate preparation and compliance with all submission requirements. For additional support or questions, applicants may contact the NICHD program office via the provided email address. Overall, this funding opportunity represents a strategic investment by NIH in advancing reproductive health innovation by lowering technical barriers and enabling access to high-quality biological testing resources. By focusing on service provision rather than direct financial awards, the program seeks to accelerate the translation of promising research into viable clinical and regulatory pathways, ultimately contributing to improved contraceptive technologies and reproductive health outcomes.